Asociace TNF-α -308G>A polymorfizmu s citlivostí na karcinom děložního čípku a prsu – systematický přehled a metaanalýza

English version České info

Východiska: Bylo provedeno několik studií týkajících se souvislosti TNF-α -308G>A s rizikem karcinomu děložního čípku (cervical cancer – CC) a prsu (breast cancer – BC). Nicméně jejich závěry nebyly konzistentní. Proto jsme provedli komplexní metaanalýzu, aby bylo možné souvislost shodněji zhodnotit ze všech příslušných případových kontrolních studiích.

Metody: Do 1. února 2019 jsme systematicky prohledali PubMed, Google Scholar a databázi Cochrane Library. Míra rizika (OR) s 95% intervalem spolehlivosti (CI) byla vypočtena pomocí modelu s pevnými nebo náhodnými efekty.

Výsledky: V této metaanalýze bylo vybráno celkem 40 případových studií zahrnujících 20 studií s 4 780 případy a 4 620 kontrolami na CC a 20 studií s 12 390 případy a 14 910 kontrolami na BC. Souhrnné výsledky ukázaly, že TNF-α -308G>A polymorfizmus byl významně spojen se zvýšeným rizikem CC (A vs. G: OR 1,277; 95% CI 1,104–1,477; p = 0,001; OR 1,333; 95% CI 1,062–1,674; p = 0,013; AG vs. GG: OR 1,307; 95% CI 1,064–1,605; p = 0,011 a AA + AG vs. GG: 95% CI 1,104–1,587; p = 0,002) a BC (AA vs. AG + GG: OR 0,094; 95% CI 0,058–0,152, p ≤ 0,001). Ve stratifikovaných analýzách podle etnicity byl polymorfizmus TNF-α -308G>A významně spojen s rizikem CC (u kavkazské a africké populace) a BC (u bělochů a Asiatů).

Závěr: Naše výsledky ukázaly, že polymorfizmus TNF-α -308G>A může být rizikovým faktorem karcinomu děložního čípku a BC v závislosti na etnicitě.

Autoři děkují Sahel Khajehnoori z Mother and Newborn Health Research Center za pomoc při revizi článku.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo: 10. 2. 2019

Přijato: 5. 3. 2019

Klíčová slova:

karcinom děložního čípku – karcinom prsu – gen TNF-α – polymorfizmus – metaanalýza

Autoři: Meraj Farbod ¹; Mojgan Zarchi Karimi ^2,3; Naeimeh Heiranizadeh ⁴; Neda Shalamzari Seifi ⁵; Javad Bafghi Mohammad Akbarian ⁶; Hossein Mohammad Jarahzadeh ⁷; Hossein Neamatzadeh ^8,9
Působiště autorů: Cancer Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran ¹; Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ²; Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran ³; Department of Surgery, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁴; Department of Emergency Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran ⁵; Department of Healthcare Management, Bam University of Medical Sciences, Bam, Iran ⁶; Department of Anesthesiology and Critical Care, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁷; Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁸; Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran ⁹
Vyšlo v časopise: Klin Onkol 2019; 32(3): 170-180
Kategorie: Přehled
prolekare.web.journal.doi_sk: https://doi.org/10.14735/amko2019170

Souhrn

Závěr: Naše výsledky ukázaly, že polymorfizmus TNF-α -308G>A může být rizikovým faktorem karcinomu děložního čípku a BC v závislosti na etnicitě.

Autoři děkují Sahel Khajehnoori z Mother and Newborn Health Research Center za pomoc při revizi článku.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Obdrženo: 10. 2. 2019

Přijato: 5. 3. 2019

Klíčová slova:

karcinom prsu – karcinom děložního čípku – gen TNF-α – polymorfizmus – metaanalýza

Zdroje

1. Gupta MK, Singh R, Banerjee M. Cytokine gene polymorphisms and their association with cervical cancer: a North Indian study. Egypt J Med Hum Genet 2016; 17 (2): 155–163. doi: 10.1016/J.EJMHG.2015.10. 005.

2. Karimi Zarchi M, Akhavan A, Gholami H et al. Evaluation of cervical cancer risk-factors in women referred to Yazd-Iran hospitals from 2002 to 2009. Asian Pac J Cancer Prev 2010; 11 (2): 537–538.

3. Behtash N, Karimi Zarchi M, Deldar M. Preoperative prognostic factors and effects of adjuvant therapy on outcomes of early stage cervical cancer in Iran. Asian Pac J Cancer Prev 2009; 10 (4): 613–618.

4. Yan Y, Zhang X. The association between CD28 gene rs3116496 polymorphism and breast cancer risk in Chinese women. Biosci Rep 2017; 37 (6): BSR20170884. doi: 10.1042/BSR20170884.

5. Mao JJ, Wu LX, Wang W et al. Nucleotide variation in ATG4A and susceptibility to cervical cancer in southwestern Chinese women. Oncol Lett 2018; 15 (3): 2992–3000. doi: 10.3892/ol.2017.7663.

6. Karimi Zarchi M, Behtash N, Sekhavat L et al. Effects of tamoxifen on the cervix and uterus in women with breast cancer: experience with Iranian patients and a literature review. Asian Pac J Cancer Prev 2009; 10 (4): 595–598.

7. Doosti M, Bakhshesh M, Zahir ST et al. Lack of evidence for a relationship between high risk human papillomaviruses and breast cancer in Iranian patients. Asian Pac J Cancer Prev 2016; 17 (9): 4357–4361.

8. Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol 2014; 35 (1): 59–61.

9. Yazdi MF, Rafieian S, Gholi-Nataj M et al. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev 2015; 16 (15): 6783–6787. doi: 10.7314/APJCP.2015.16.15.6783.

10. Sheikhpour E, Noorbakhsh P, Foroughi E et al. A survey on the role of interleukin-10 in breast cancer: a narrative. Rep Biochem Mol Biol 2017; 7 (1): 30–37.

11. Sobhan MR, Mahdinezhad-Yazdi M, Aghili K et al. Association of TNF-α-308 G > A and -238G > A polymorphisms with knee osteoarthritis risk: a case-control study and meta-analysis. J Orthop 2018; 15 (3): 747–753. doi: 10.1016/J.JOR.2018.05.047.

12. Azarpira MR, Ghilian MM, Sobhan MR et al. Association of MTHFR and TNF-α genes polymorphisms with susceptibility to Legg-Calve-Perthes disease in Iranian children: a case-control study. J Orthop 2018; 15 (4): 984–987. doi: 10.1016/j.jor.2018.08.042.

13. Aslebahar F, Neamatzadeh H, Meibodi B et al. Association of tumor necrosis factor-α (TNF-α) -308G>A and -238G>A polymorphisms with recurrent pregnancy loss risk: a meta-analysis. Int J Fertil Steril 2019; 12 (4): 284–292. doi: 10.22074/ijfs.2019.5454.

14. Jang WH, Yang YI, Yea SS et al. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 2001; 166 (1): 41–46.

15. Calhoun ES, McGovern RM, Janney CA et al. Host genetic polymorphism analysis in cervical cancer. Clin Chem 2002; 48 (8): 1218–1224.

16. Stanczuk GA, Sibanda EN, Tswana SA et al. Polymorphism at the -308-promoter position of the tumor necrosis factor-alpha (TNF-αlpha) gene and cervical cancer. Int J Gynecol Cancer 13 (2): 148–153.

17. Gostout BS, Poland GA, Calhoun ES et al. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol Oncol 2003; 88 (3): 326–332.

18. Duarte I, Santos A, Sousa H et al. G-308A TNF-α polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 2005; 334 (2): 588–592. doi: 10.1016/j.bbrc.2005.06.137.

19. Deshpande A, Nolan JP, White PS et al. TNF-α promoter polymorphisms and susceptibility to human papillomavirus 16–associated cervical cancer. J Infect Dis 2005; 191 (6): 969–976. doi: 10.1086/427826.

20. Govan VA, Constant D, Hoffman M et al. The allelic distribution of -308 tumor necrosis factor-alpha gene polymorphism in south African women with cervical cancer and control women. BMC Cancer 2006; 6 (1): 24. doi: 10.1186/1471-2407-6-24.

21. Kohaar I, Thakur N, Salhan S et al. TNFalpha-308G/A polymorphism as a risk factor for HPV associated cervical cancer in Indian population. Cell Oncol 2007; 29 (3): 249–256.

22. Wang SS, Bratti MC, Rodríguez AC et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J Infect Dis 2009; 199 (1): 20–30. doi: 10.1086/595563.

23. Singh H, Jain M, Sachan R et al. Association of TNFA (-308G>A) and IL-10 (-819C>T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer 2009; 19 (7): 1190–1194. doi: 10.1111/IGC.0b013e3181a3a3af.

24. Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol 2010; 116 (3): 544–548. doi: 10.1016/j.ygyno.2009.10.084.

25. Zu F, Ai X, La L et al. A preliminary study of TNFa gene 308 single nucleotide polymorphism with cervical cancer risk and HPV subtype infection in southern Xinjiang Uygur patients. Chinese J Obstet Gynecol 2010; 45 (9): 709–711.

26. Wang Q, Zhang C, Walayat S et al. Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol 2011; 158 (2): 330–333. doi: 10.1016/j.ejogrb.2011.05.019.

27. Zuo F, Liang W, Ouyang Y et al. Association of TNF-α gene promoter polymorphisms with susceptibility of cervical cancer in southwest China. Lab Med 2011; 42 (5): 287–290. doi: 10.1309/LM532DSPDUXIRJVN.

28. Wang N, Yin D, Zhang S et al. TNF-αlpha rs1800629 polymorphism is not associated with hpv infection or cervical cancer in the Chinese population. PLoS One 2012; 7 (9): e45246. doi: 10.1371/journal.pone.0045246.

29. Barbisan G, Pérez LO, Contreras A et al. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumor Biol 2012; 33 (5): 1549–1556. doi: 10.1007/s13277-012-0408-1.

30. Badano I, Stietz SM, Schurr TG et al. Analysis of TNFα promoter SNPs and the risk of cervical cancer in urban populations of Posadas (Misiones, Argentina). J Clin Virol 2012; 53 (1): 54–59. doi: 10.1016/j.jcv.2011.09.030.

31. Sousa H, Oliveira S, Santos AM et al. Tumour necrosis factor alpha 308 G/A is a risk marker for the progression from high-grade lesions to invasive cervical cancer. Tumor Biol 2014; 35 (3): 2561–2564. doi: 10.1007/s13277-013-1337-3.

32. Zidi S, Stayoussef M, Zouidi F et al. Tumor necrosis factor alpha (-238 / -308) and TNFRII-VNTR (-322) polymorphisms as genetic biomarkers of susceptibility to develop cervical cancer among Tunisians. Pathol Oncol Res 2015; 21 (2): 339–345. doi: 10.1007/s12253-014-9826-2.

33. Roszak A, Misztal M, Sowińska A et al. TNF-α -308 G/A as a risk marker of cervical cancer progression in the Polish population. Mol Diagn Ther 2015; 19 (1): 53–57. doi: 10.1007/s40291-015-0130-y.

34. Mestiri S, Bouaouina N, Ahmed SB et al. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 2001; 91 (4): 672–678.

35. Park KS, Mok JW, Ko HE et al. Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 2002; 29 (1): 7–10.

36. Giordani L, Bruzzi P, Lasalandra C et al. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 2003; 49 (10): 1664–1667. doi: 10.1373/49.10.1664.

37. Azmy IA, Balasubramanian SP, Wilson AG et al. Role of tumour necrosis factor gene polymorphisms (-308 and -238) in breast cancer susceptibility and severity. Breast Cancer Res 2004; 6 (4): R395–R400. doi: 10.1186/bcr802.

38. Smith KC, Bateman AC, Fussell HM et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004; 31 (4): 167–173. doi: 10.1111/j.1365-2370.2004.00462.x.

39. Kamali-Sarvestani E, Merat A, Talei AR. Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-α and TNF-β) and gamma interferon (IFN-γ) among Iranian women with breast cancer. Cancer Lett 2005; 223 (1): 113–119. doi: 10.1016/J.CANLET.2004.09.025.

40. Scola L, Vaglica M, Crivello A et al. Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 2006; 1089 (1): 104–109. doi: 10.1196/annals.1386.017.

41. Gallicchio L, McSorley MA, Newschaffer CJ et al. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 2007; 31 (2): 95–101. doi: 10.1016/j.cdp.2007.02.004.

42. Gaudet MM, Egan KM, Lissowska J et al. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF–LTA) and breast cancer risk. Hum Genet 2007; 121 (3–4): 483–490. doi: 10.1007/s00439-006-0315-x.

43. Sirotkovic-Skerlev M, Cacev T, Krizanac S et al. TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol 2007; 83 (1): 54–58. doi: 10.1016/j.yexmp.2006.11.004.

44. Gonullu G, Basturk B, Evrensel T et al. Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 2007; 28 (11): 1728–1733.

45. Ostashkin AS, Malivanova TF, Lurchenko VA et al. Tumor necrosis factor gene polymorphisms in breast cancer patients. Genetika 2008; 44 (9): 1275–1280.

46. Kohaar I, Tiwari P, Kumar R et al. Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res Treat 2009; 114 (2): 347–355. doi: 10.1007/s10549-008-0006-5.

47. MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 2010; 120 (3): 727–736. doi: 10.1007/s10549-009-0489-8.

48. Pooja S, Francis A, Bid HK et al. Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India. Breast Cancer Res Treat 2011; 126 (3): 739–747. doi: 10.1007/s10549-010-1175-6.

49. Karakus N, Kara N, Ulusoy AN et al. Tumor necrosis factor alpha and beta and interferon gamma gene polymorphisms in Turkish breast cancer patients. DNA Cell Biol 2011; 30 (6): 371–377. doi: 10.1089/dna.2010. 1113.

50. Madeleine MM, Johnson LG, Malkki M et al. Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat 2011; 129 (3): 887–899. doi: 10.1007/s10549-011-1520-4.

51. Gómez Flores-Ramos L, Escoto-De Dios A, Puebla-Pérez AM et al. Association of the tumor necrosis factor-alpha -308G>A polymorphism with breast cancer in Mexican women. Genet Mol Res 2013; 12 (4): 5680–5693. doi: 10.4238/2013.November.18.17.

52. Aslebahar F, Neamatzadeh H, Meibodi B et al. Association of tumor necrosis Factor-α (TNF-α) -308G>A and -238G>A polymorphisms with recurrent pregnancy loss risk: a meta-analysis. Int J Fertil Steril 2019; 12 (4): 284–292. doi: 10.22074/ijfs.2019.5454.

53. Abdel Galil SM, Ezzeldin N, Fawzy F et al. The single-nucleotide polymorphism (SNP) of tumor necrosis factor α−308G/A gene is associated with early-onset primary knee osteoarthritis in an Egyptian female population. Clin Rheumatol 2017; 36 (11): 2525–2530. doi: 10.1007/s10067-017-3727-1.

54. Seifart C, Plagens A, Dempfle A et al. TNF-αlpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 2005; 21 (3): 157–165.

55. Jin Y. Association of single nucleotide polymorphisms in tumor necrosis factor-alpha with cervical cancer susceptibility. Cell Biochem Biophys 2015; 71 (1): 77–84. doi: 10.1007/s12013-014-0165-4.

56. Jin G, Zhao Y, Sun S et al. Association between the tumor necrosis factor alpha gene -308G> A polymorphism and the risk of breast cancer: a meta-analysis. Tumor Biol 2014; 35 (12): 12091–12098. doi: 10.1007/s13277-014-2510-z.

57. Cai J, Yang MY, Hou N et al. Association of tumor necrosis factor-α 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis. Genet Mol Res 2015; 14 (4): 16102–16112. doi: 10.4238/2015.December.7.22.

58. Barbisan G, Pérez LO, Contreras A et al. TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumor Biol 2012; 33 (5): 1549–1556. doi: 10.1007/s13277-012-0408-1.